Helius Medical Technologies, Inc.
Helius Medical Technologies, Inc. HSDT Peers
See (HSDT) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HSDT | $9.40 | -3.69% | 71M | -0.36 | -$26.40 | N/A |
| ABT | $134.44 | +0.25% | 233.9B | 17.48 | $7.69 | +1.70% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| BSX | $104.32 | +0.67% | 154.3B | 76.15 | $1.37 | N/A |
| SYK | $395.28 | +0.89% | 151.1B | 53.49 | $7.39 | +0.84% |
| MDT | $88.39 | +0.12% | 113.3B | 24.48 | $3.61 | +3.18% |
| EW | $76.79 | -0.30% | 45B | 31.73 | $2.42 | N/A |
| DXCM | $82.93 | -0.78% | 32.5B | 62.35 | $1.33 | N/A |
| STE | $237.55 | -0.29% | 23.4B | 38.56 | $6.16 | +0.96% |
| PHG | $24.17 | -1.43% | 22.4B | 80.57 | $0.30 | +3.67% |
Stock Comparison
HSDT vs ABT Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, ABT has a market cap of 233.9B. Regarding current trading prices, HSDT is priced at $9.40, while ABT trades at $134.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas ABT's P/E ratio is 17.48. In terms of profitability, HSDT's ROE is -4.19%, compared to ABT's ROE of +0.31%. Regarding short-term risk, HSDT is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs BSX-PA Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, HSDT is priced at $9.40, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, HSDT's ROE is -4.19%, compared to BSX-PA's ROE of +0.10%. Regarding short-term risk, HSDT is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs BSX Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, BSX has a market cap of 154.3B. Regarding current trading prices, HSDT is priced at $9.40, while BSX trades at $104.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas BSX's P/E ratio is 76.15. In terms of profitability, HSDT's ROE is -4.19%, compared to BSX's ROE of +0.10%. Regarding short-term risk, HSDT is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs SYK Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, SYK has a market cap of 151.1B. Regarding current trading prices, HSDT is priced at $9.40, while SYK trades at $395.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas SYK's P/E ratio is 53.49. In terms of profitability, HSDT's ROE is -4.19%, compared to SYK's ROE of +0.11%. Regarding short-term risk, HSDT is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs MDT Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, MDT has a market cap of 113.3B. Regarding current trading prices, HSDT is priced at $9.40, while MDT trades at $88.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas MDT's P/E ratio is 24.48. In terms of profitability, HSDT's ROE is -4.19%, compared to MDT's ROE of +0.10%. Regarding short-term risk, HSDT is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs EW Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, EW has a market cap of 45B. Regarding current trading prices, HSDT is priced at $9.40, while EW trades at $76.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas EW's P/E ratio is 31.73. In terms of profitability, HSDT's ROE is -4.19%, compared to EW's ROE of +0.49%. Regarding short-term risk, HSDT is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs DXCM Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, DXCM has a market cap of 32.5B. Regarding current trading prices, HSDT is priced at $9.40, while DXCM trades at $82.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas DXCM's P/E ratio is 62.35. In terms of profitability, HSDT's ROE is -4.19%, compared to DXCM's ROE of +0.24%. Regarding short-term risk, HSDT is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs STE Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, STE has a market cap of 23.4B. Regarding current trading prices, HSDT is priced at $9.40, while STE trades at $237.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas STE's P/E ratio is 38.56. In terms of profitability, HSDT's ROE is -4.19%, compared to STE's ROE of +0.09%. Regarding short-term risk, HSDT is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs PHG Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, PHG has a market cap of 22.4B. Regarding current trading prices, HSDT is priced at $9.40, while PHG trades at $24.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas PHG's P/E ratio is 80.57. In terms of profitability, HSDT's ROE is -4.19%, compared to PHG's ROE of +0.03%. Regarding short-term risk, HSDT is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs PODD Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, PODD has a market cap of 21.2B. Regarding current trading prices, HSDT is priced at $9.40, while PODD trades at $301.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas PODD's P/E ratio is 54.24. In terms of profitability, HSDT's ROE is -4.19%, compared to PODD's ROE of +0.35%. Regarding short-term risk, HSDT is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs ZBH Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, ZBH has a market cap of 18.5B. Regarding current trading prices, HSDT is priced at $9.40, while ZBH trades at $93.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas ZBH's P/E ratio is 20.82. In terms of profitability, HSDT's ROE is -4.19%, compared to ZBH's ROE of +0.07%. Regarding short-term risk, HSDT is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs ABMD Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, HSDT is priced at $9.40, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas ABMD's P/E ratio is 65.36. In terms of profitability, HSDT's ROE is -4.19%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, HSDT is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs ALGN Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, ALGN has a market cap of 14.3B. Regarding current trading prices, HSDT is priced at $9.40, while ALGN trades at $196.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas ALGN's P/E ratio is 35.72. In terms of profitability, HSDT's ROE is -4.19%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, HSDT is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs SNN Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, SNN has a market cap of 13.2B. Regarding current trading prices, HSDT is priced at $9.40, while SNN trades at $30.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas SNN's P/E ratio is 32.21. In terms of profitability, HSDT's ROE is -4.19%, compared to SNN's ROE of +0.08%. Regarding short-term risk, HSDT is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs SWAV Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, HSDT is priced at $9.40, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas SWAV's P/E ratio is 78.76. In terms of profitability, HSDT's ROE is -4.19%, compared to SWAV's ROE of +0.14%. Regarding short-term risk, HSDT is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs PEN Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, PEN has a market cap of 9.7B. Regarding current trading prices, HSDT is priced at $9.40, while PEN trades at $251.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas PEN's P/E ratio is 232.46. In terms of profitability, HSDT's ROE is -4.19%, compared to PEN's ROE of +0.04%. Regarding short-term risk, HSDT is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs GMED Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, GMED has a market cap of 8B. Regarding current trading prices, HSDT is priced at $9.40, while GMED trades at $59.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas GMED's P/E ratio is 44.16. In terms of profitability, HSDT's ROE is -4.19%, compared to GMED's ROE of +0.05%. Regarding short-term risk, HSDT is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs BIO Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, BIO has a market cap of 6.8B. Regarding current trading prices, HSDT is priced at $9.40, while BIO trades at $251.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas BIO's P/E ratio is -3.29. In terms of profitability, HSDT's ROE is -4.19%, compared to BIO's ROE of -0.32%. Regarding short-term risk, HSDT is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs BIO-B Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, BIO-B has a market cap of 6.8B. Regarding current trading prices, HSDT is priced at $9.40, while BIO-B trades at $250.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas BIO-B's P/E ratio is -3.27. In terms of profitability, HSDT's ROE is -4.19%, compared to BIO-B's ROE of -0.32%. Regarding short-term risk, HSDT is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs BRKR Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, BRKR has a market cap of 6.4B. Regarding current trading prices, HSDT is priced at $9.40, while BRKR trades at $42.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas BRKR's P/E ratio is 81.63. In terms of profitability, HSDT's ROE is -4.19%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, HSDT is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs GKOS Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, GKOS has a market cap of 5.9B. Regarding current trading prices, HSDT is priced at $9.40, while GKOS trades at $103.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas GKOS's P/E ratio is -45.59. In terms of profitability, HSDT's ROE is -4.19%, compared to GKOS's ROE of -0.17%. Regarding short-term risk, HSDT is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs NARI Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, HSDT is priced at $9.40, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas NARI's P/E ratio is -59.24. In terms of profitability, HSDT's ROE is -4.19%, compared to NARI's ROE of -0.18%. Regarding short-term risk, HSDT is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs IRTC Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, IRTC has a market cap of 4.5B. Regarding current trading prices, HSDT is priced at $9.40, while IRTC trades at $142.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas IRTC's P/E ratio is -45.66. In terms of profitability, HSDT's ROE is -4.19%, compared to IRTC's ROE of -1.13%. Regarding short-term risk, HSDT is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs TMDX Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, TMDX has a market cap of 4.4B. Regarding current trading prices, HSDT is priced at $9.40, while TMDX trades at $129.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas TMDX's P/E ratio is 90.98. In terms of profitability, HSDT's ROE is -4.19%, compared to TMDX's ROE of +0.22%. Regarding short-term risk, HSDT is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs ITGR Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, ITGR has a market cap of 4.2B. Regarding current trading prices, HSDT is priced at $9.40, while ITGR trades at $121.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas ITGR's P/E ratio is 56.54. In terms of profitability, HSDT's ROE is -4.19%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, HSDT is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs INSP Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, INSP has a market cap of 3.8B. Regarding current trading prices, HSDT is priced at $9.40, while INSP trades at $128.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas INSP's P/E ratio is 58.67. In terms of profitability, HSDT's ROE is -4.19%, compared to INSP's ROE of +0.10%. Regarding short-term risk, HSDT is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs AXNX Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, HSDT is priced at $9.40, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas AXNX's P/E ratio is -709.80. In terms of profitability, HSDT's ROE is -4.19%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, HSDT is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs PRCT Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, PRCT has a market cap of 3.2B. Regarding current trading prices, HSDT is priced at $9.40, while PRCT trades at $57.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas PRCT's P/E ratio is -34.27. In terms of profitability, HSDT's ROE is -4.19%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, HSDT is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs LIVN Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, LIVN has a market cap of 2.5B. Regarding current trading prices, HSDT is priced at $9.40, while LIVN trades at $46.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas LIVN's P/E ratio is -11.33. In terms of profitability, HSDT's ROE is -4.19%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, HSDT is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs NUVA Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, HSDT is priced at $9.40, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas NUVA's P/E ratio is 75.00. In terms of profitability, HSDT's ROE is -4.19%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, HSDT is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs UFPT Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, UFPT has a market cap of 1.9B. Regarding current trading prices, HSDT is priced at $9.40, while UFPT trades at $249.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas UFPT's P/E ratio is 30.63. In terms of profitability, HSDT's ROE is -4.19%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, HSDT is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs CNMD Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, CNMD has a market cap of 1.7B. Regarding current trading prices, HSDT is priced at $9.40, while CNMD trades at $54.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas CNMD's P/E ratio is 14.26. In terms of profitability, HSDT's ROE is -4.19%, compared to CNMD's ROE of +0.13%. Regarding short-term risk, HSDT is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs ATEC Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, HSDT is priced at $9.40, while ATEC trades at $10.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas ATEC's P/E ratio is -9.64. In terms of profitability, HSDT's ROE is -4.19%, compared to ATEC's ROE of -2.58%. Regarding short-term risk, HSDT is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs AORT Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, AORT has a market cap of 1.3B. Regarding current trading prices, HSDT is priced at $9.40, while AORT trades at $30.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas AORT's P/E ratio is -60.24. In terms of profitability, HSDT's ROE is -4.19%, compared to AORT's ROE of -0.07%. Regarding short-term risk, HSDT is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs HSKA Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, HSDT is priced at $9.40, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas HSKA's P/E ratio is -62.49. In terms of profitability, HSDT's ROE is -4.19%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, HSDT is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs ESTA Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, ESTA has a market cap of 1.3B. Regarding current trading prices, HSDT is priced at $9.40, while ESTA trades at $43.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas ESTA's P/E ratio is -13.96. In terms of profitability, HSDT's ROE is -4.19%, compared to ESTA's ROE of -2.10%. Regarding short-term risk, HSDT is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs AHCO Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, AHCO has a market cap of 1.3B. Regarding current trading prices, HSDT is priced at $9.40, while AHCO trades at $9.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas AHCO's P/E ratio is 16.07. In terms of profitability, HSDT's ROE is -4.19%, compared to AHCO's ROE of +0.06%. Regarding short-term risk, HSDT is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs TNDM Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, HSDT is priced at $9.40, while TNDM trades at $16.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas TNDM's P/E ratio is -6.01. In terms of profitability, HSDT's ROE is -4.19%, compared to TNDM's ROE of -0.83%. Regarding short-term risk, HSDT is more volatile compared to TNDM. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs SILK Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, HSDT is priced at $9.40, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas SILK's P/E ratio is -18.96. In terms of profitability, HSDT's ROE is -4.19%, compared to SILK's ROE of -0.29%. Regarding short-term risk, HSDT is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs FNA Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, HSDT is priced at $9.40, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas FNA's P/E ratio is -19.83. In terms of profitability, HSDT's ROE is -4.19%, compared to FNA's ROE of -0.36%. Regarding short-term risk, HSDT is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs INMD Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, INMD has a market cap of 1.1B. Regarding current trading prices, HSDT is priced at $9.40, while INMD trades at $15.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas INMD's P/E ratio is 6.80. In terms of profitability, HSDT's ROE is -4.19%, compared to INMD's ROE of +0.25%. Regarding short-term risk, HSDT is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs IART Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, IART has a market cap of 1B. Regarding current trading prices, HSDT is priced at $9.40, while IART trades at $13.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas IART's P/E ratio is -35.50. In terms of profitability, HSDT's ROE is -4.19%, compared to IART's ROE of -0.03%. Regarding short-term risk, HSDT is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs SSII Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, SSII has a market cap of 1B. Regarding current trading prices, HSDT is priced at $9.40, while SSII trades at $5.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas SSII's P/E ratio is -66.62. In terms of profitability, HSDT's ROE is -4.19%, compared to SSII's ROE of -1.33%. Regarding short-term risk, HSDT is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for HSDT.
HSDT vs CSII Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, HSDT is priced at $9.40, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas CSII's P/E ratio is -20.83. In terms of profitability, HSDT's ROE is -4.19%, compared to CSII's ROE of -0.14%. Regarding short-term risk, HSDT is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs SIBN Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, SIBN has a market cap of 787.1M. Regarding current trading prices, HSDT is priced at $9.40, while SIBN trades at $18.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas SIBN's P/E ratio is -29.32. In terms of profitability, HSDT's ROE is -4.19%, compared to SIBN's ROE of -0.16%. Regarding short-term risk, HSDT is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs IRMD Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, IRMD has a market cap of 785.8M. Regarding current trading prices, HSDT is priced at $9.40, while IRMD trades at $61.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas IRMD's P/E ratio is 39.87. In terms of profitability, HSDT's ROE is -4.19%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, HSDT is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs CRY Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, HSDT is priced at $9.40, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas CRY's P/E ratio is 425.71. In terms of profitability, HSDT's ROE is -4.19%, compared to CRY's ROE of -0.07%. Regarding short-term risk, HSDT is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs CBLL Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, CBLL has a market cap of 684.2M. Regarding current trading prices, HSDT is priced at $9.40, while CBLL trades at $18.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas CBLL's P/E ratio is -15.14. In terms of profitability, HSDT's ROE is -4.19%, compared to CBLL's ROE of -1.64%. Regarding short-term risk, HSDT is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs APEN Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, HSDT is priced at $9.40, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas APEN's P/E ratio is -9.43. In terms of profitability, HSDT's ROE is -4.19%, compared to APEN's ROE of -0.85%. Regarding short-term risk, HSDT is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs BFLY-WT Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, BFLY-WT has a market cap of 577.2M. Regarding current trading prices, HSDT is priced at $9.40, while BFLY-WT trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, HSDT's ROE is -4.19%, compared to BFLY-WT's ROE of -0.33%. Regarding short-term risk, HSDT is more volatile compared to BFLY-WT. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs AVNS Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, AVNS has a market cap of 571.1M. Regarding current trading prices, HSDT is priced at $9.40, while AVNS trades at $12.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas AVNS's P/E ratio is -1.49. In terms of profitability, HSDT's ROE is -4.19%, compared to AVNS's ROE of -0.37%. Regarding short-term risk, HSDT is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs KIDS Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, KIDS has a market cap of 556.8M. Regarding current trading prices, HSDT is priced at $9.40, while KIDS trades at $22.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas KIDS's P/E ratio is -12.77. In terms of profitability, HSDT's ROE is -4.19%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, HSDT is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs RXST Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, RXST has a market cap of 530.3M. Regarding current trading prices, HSDT is priced at $9.40, while RXST trades at $13.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas RXST's P/E ratio is -19.77. In terms of profitability, HSDT's ROE is -4.19%, compared to RXST's ROE of -0.10%. Regarding short-term risk, HSDT is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs AXGN Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, AXGN has a market cap of 497.8M. Regarding current trading prices, HSDT is priced at $9.40, while AXGN trades at $10.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas AXGN's P/E ratio is -68.31. In terms of profitability, HSDT's ROE is -4.19%, compared to AXGN's ROE of -0.07%. Regarding short-term risk, HSDT is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs PACB Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, PACB has a market cap of 480.1M. Regarding current trading prices, HSDT is priced at $9.40, while PACB trades at $1.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas PACB's P/E ratio is -0.58. In terms of profitability, HSDT's ROE is -4.19%, compared to PACB's ROE of -1.70%. Regarding short-term risk, HSDT is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for HSDT.
HSDT vs BFLY Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, BFLY has a market cap of 479.7M. Regarding current trading prices, HSDT is priced at $9.40, while BFLY trades at $1.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas BFLY's P/E ratio is -6.47. In terms of profitability, HSDT's ROE is -4.19%, compared to BFLY's ROE of -0.33%. Regarding short-term risk, HSDT is more volatile compared to BFLY. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs CTKB Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, CTKB has a market cap of 476.2M. Regarding current trading prices, HSDT is priced at $9.40, while CTKB trades at $3.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas CTKB's P/E ratio is -41.78. In terms of profitability, HSDT's ROE is -4.19%, compared to CTKB's ROE of -0.03%. Regarding short-term risk, HSDT is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs BVS Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, BVS has a market cap of 465.8M. Regarding current trading prices, HSDT is priced at $9.40, while BVS trades at $7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas BVS's P/E ratio is -14.62. In terms of profitability, HSDT's ROE is -4.19%, compared to BVS's ROE of -0.21%. Regarding short-term risk, HSDT is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs SMLR Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, SMLR has a market cap of 451.1M. Regarding current trading prices, HSDT is priced at $9.40, while SMLR trades at $40.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas SMLR's P/E ratio is -16.92. In terms of profitability, HSDT's ROE is -4.19%, compared to SMLR's ROE of -0.21%. Regarding short-term risk, HSDT is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs OFIX Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, OFIX has a market cap of 435.7M. Regarding current trading prices, HSDT is priced at $9.40, while OFIX trades at $11.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas OFIX's P/E ratio is -3.01. In terms of profitability, HSDT's ROE is -4.19%, compared to OFIX's ROE of -0.28%. Regarding short-term risk, HSDT is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs SRDX Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, SRDX has a market cap of 428.8M. Regarding current trading prices, HSDT is priced at $9.40, while SRDX trades at $29.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas SRDX's P/E ratio is -21.42. In terms of profitability, HSDT's ROE is -4.19%, compared to SRDX's ROE of -0.17%. Regarding short-term risk, HSDT is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs TMCI Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, TMCI has a market cap of 388.8M. Regarding current trading prices, HSDT is priced at $9.40, while TMCI trades at $6.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas TMCI's P/E ratio is -7.27. In terms of profitability, HSDT's ROE is -4.19%, compared to TMCI's ROE of -0.49%. Regarding short-term risk, HSDT is more volatile compared to TMCI. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs SENS Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, SENS has a market cap of 379M. Regarding current trading prices, HSDT is priced at $9.40, while SENS trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas SENS's P/E ratio is -4.57. In terms of profitability, HSDT's ROE is -4.19%, compared to SENS's ROE of -7.46%. Regarding short-term risk, HSDT is more volatile compared to SENS. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs OM Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, OM has a market cap of 370.4M. Regarding current trading prices, HSDT is priced at $9.40, while OM trades at $20.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas OM's P/E ratio is -0.73. In terms of profitability, HSDT's ROE is -4.19%, compared to OM's ROE of -1.45%. Regarding short-term risk, HSDT is more volatile compared to OM. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs VREX Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, VREX has a market cap of 365.2M. Regarding current trading prices, HSDT is priced at $9.40, while VREX trades at $8.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas VREX's P/E ratio is -8.54. In terms of profitability, HSDT's ROE is -4.19%, compared to VREX's ROE of -0.08%. Regarding short-term risk, HSDT is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs NPCE Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, NPCE has a market cap of 340.8M. Regarding current trading prices, HSDT is priced at $9.40, while NPCE trades at $10.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas NPCE's P/E ratio is -12.67. In terms of profitability, HSDT's ROE is -4.19%, compared to NPCE's ROE of -1.40%. Regarding short-term risk, HSDT is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs NNOX Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, NNOX has a market cap of 339.2M. Regarding current trading prices, HSDT is priced at $9.40, while NNOX trades at $5.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas NNOX's P/E ratio is -5.85. In terms of profitability, HSDT's ROE is -4.19%, compared to NNOX's ROE of -0.31%. Regarding short-term risk, HSDT is more volatile compared to NNOX. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs CLPT Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, CLPT has a market cap of 330.7M. Regarding current trading prices, HSDT is priced at $9.40, while CLPT trades at $11.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas CLPT's P/E ratio is -15.39. In terms of profitability, HSDT's ROE is -4.19%, compared to CLPT's ROE of -0.78%. Regarding short-term risk, HSDT is more volatile compared to CLPT. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs CERS Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, CERS has a market cap of 294.4M. Regarding current trading prices, HSDT is priced at $9.40, while CERS trades at $1.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas CERS's P/E ratio is -15.40. In terms of profitability, HSDT's ROE is -4.19%, compared to CERS's ROE of -0.35%. Regarding short-term risk, HSDT is more volatile compared to CERS. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs ZIMV Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, ZIMV has a market cap of 286.2M. Regarding current trading prices, HSDT is priced at $9.40, while ZIMV trades at $10.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas ZIMV's P/E ratio is -11.39. In terms of profitability, HSDT's ROE is -4.19%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, HSDT is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs BSGM Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, BSGM has a market cap of 284.1M. Regarding current trading prices, HSDT is priced at $9.40, while BSGM trades at $10.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas BSGM's P/E ratio is -19.64. In terms of profitability, HSDT's ROE is -4.19%, compared to BSGM's ROE of -35.30%. Regarding short-term risk, HSDT is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for HSDT.
HSDT vs VMD Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, VMD has a market cap of 282.6M. Regarding current trading prices, HSDT is priced at $9.40, while VMD trades at $7.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas VMD's P/E ratio is 23.83. In terms of profitability, HSDT's ROE is -4.19%, compared to VMD's ROE of +0.10%. Regarding short-term risk, HSDT is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs CATX Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, CATX has a market cap of 273.2M. Regarding current trading prices, HSDT is priced at $9.40, while CATX trades at $3.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas CATX's P/E ratio is -2.99. In terms of profitability, HSDT's ROE is -4.19%, compared to CATX's ROE of -0.27%. Regarding short-term risk, HSDT is more volatile compared to CATX. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs PTHL Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, PTHL has a market cap of 272.9M. Regarding current trading prices, HSDT is priced at $9.40, while PTHL trades at $19.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas PTHL's P/E ratio is -383.00. In terms of profitability, HSDT's ROE is -4.19%, compared to PTHL's ROE of -0.30%. Regarding short-term risk, HSDT is more volatile compared to PTHL. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs QTRX Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, QTRX has a market cap of 271.2M. Regarding current trading prices, HSDT is priced at $9.40, while QTRX trades at $6.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas QTRX's P/E ratio is -5.63. In terms of profitability, HSDT's ROE is -4.19%, compared to QTRX's ROE of -0.15%. Regarding short-term risk, HSDT is more volatile compared to QTRX. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs SNWV Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, SNWV has a market cap of 270.8M. Regarding current trading prices, HSDT is priced at $9.40, while SNWV trades at $31.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas SNWV's P/E ratio is -5.08. In terms of profitability, HSDT's ROE is -4.19%, compared to SNWV's ROE of +1.00%. Regarding short-term risk, HSDT is more volatile compared to SNWV. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs BWAY Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, BWAY has a market cap of 250.2M. Regarding current trading prices, HSDT is priced at $9.40, while BWAY trades at $13.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas BWAY's P/E ratio is 60.18. In terms of profitability, HSDT's ROE is -4.19%, compared to BWAY's ROE of +0.06%. Regarding short-term risk, HSDT is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs MASS Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, MASS has a market cap of 238.5M. Regarding current trading prices, HSDT is priced at $9.40, while MASS trades at $6.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas MASS's P/E ratio is -3.00. In terms of profitability, HSDT's ROE is -4.19%, compared to MASS's ROE of -0.13%. Regarding short-term risk, HSDT is more volatile compared to MASS. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs MXCT Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, MXCT has a market cap of 237.6M. Regarding current trading prices, HSDT is priced at $9.40, while MXCT trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas MXCT's P/E ratio is -5.59. In terms of profitability, HSDT's ROE is -4.19%, compared to MXCT's ROE of -0.20%. Regarding short-term risk, HSDT is more volatile compared to MXCT. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs TCMD Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, TCMD has a market cap of 235.5M. Regarding current trading prices, HSDT is priced at $9.40, while TCMD trades at $10.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas TCMD's P/E ratio is 15.35. In terms of profitability, HSDT's ROE is -4.19%, compared to TCMD's ROE of +0.08%. Regarding short-term risk, HSDT is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs NVRO Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, HSDT is priced at $9.40, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas NVRO's P/E ratio is -1.91. In terms of profitability, HSDT's ROE is -4.19%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, HSDT is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs SGHT Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, SGHT has a market cap of 217.7M. Regarding current trading prices, HSDT is priced at $9.40, while SGHT trades at $4.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas SGHT's P/E ratio is -4.30. In terms of profitability, HSDT's ROE is -4.19%, compared to SGHT's ROE of -0.55%. Regarding short-term risk, HSDT is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs EYES Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, HSDT is priced at $9.40, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas EYES's P/E ratio is N/A. In terms of profitability, HSDT's ROE is -4.19%, compared to EYES's ROE of -0.26%. Regarding short-term risk, HSDT is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs INGN Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, INGN has a market cap of 201.4M. Regarding current trading prices, HSDT is priced at $9.40, while INGN trades at $7.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas INGN's P/E ratio is -6.51. In terms of profitability, HSDT's ROE is -4.19%, compared to INGN's ROE of -0.15%. Regarding short-term risk, HSDT is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs TLSI Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, TLSI has a market cap of 192.5M. Regarding current trading prices, HSDT is priced at $9.40, while TLSI trades at $5.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas TLSI's P/E ratio is -4.61. In terms of profitability, HSDT's ROE is -4.19%, compared to TLSI's ROE of +1.04%. Regarding short-term risk, HSDT is more volatile compared to TLSI. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs PROF Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, PROF has a market cap of 179.6M. Regarding current trading prices, HSDT is priced at $9.40, while PROF trades at $5.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas PROF's P/E ratio is -4.94. In terms of profitability, HSDT's ROE is -4.19%, compared to PROF's ROE of -0.70%. Regarding short-term risk, HSDT is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs ELMD Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, ELMD has a market cap of 174.3M. Regarding current trading prices, HSDT is priced at $9.40, while ELMD trades at $20.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas ELMD's P/E ratio is 26.30. In terms of profitability, HSDT's ROE is -4.19%, compared to ELMD's ROE of +0.17%. Regarding short-term risk, HSDT is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs CVRX Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, CVRX has a market cap of 171.6M. Regarding current trading prices, HSDT is priced at $9.40, while CVRX trades at $6.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas CVRX's P/E ratio is -3.07. In terms of profitability, HSDT's ROE is -4.19%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, HSDT is more volatile compared to CVRX. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs ANIK Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, ANIK has a market cap of 161.3M. Regarding current trading prices, HSDT is priced at $9.40, while ANIK trades at $11.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas ANIK's P/E ratio is -15.00. In terms of profitability, HSDT's ROE is -4.19%, compared to ANIK's ROE of -0.33%. Regarding short-term risk, HSDT is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs RPID Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, RPID has a market cap of 159.1M. Regarding current trading prices, HSDT is priced at $9.40, while RPID trades at $3.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas RPID's P/E ratio is -3.52. In terms of profitability, HSDT's ROE is -4.19%, compared to RPID's ROE of -0.56%. Regarding short-term risk, HSDT is more volatile compared to RPID. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs LNSR Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, LNSR has a market cap of 156.7M. Regarding current trading prices, HSDT is priced at $9.40, while LNSR trades at $13.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas LNSR's P/E ratio is -2.71. In terms of profitability, HSDT's ROE is -4.19%, compared to LNSR's ROE of -5.28%. Regarding short-term risk, HSDT is more volatile compared to LNSR. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs RCEL Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, RCEL has a market cap of 143.3M. Regarding current trading prices, HSDT is priced at $9.40, while RCEL trades at $5.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas RCEL's P/E ratio is -2.47. In terms of profitability, HSDT's ROE is -4.19%, compared to RCEL's ROE of -3.38%. Regarding short-term risk, HSDT is more volatile compared to RCEL. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs AVR Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, AVR has a market cap of 141.7M. Regarding current trading prices, HSDT is priced at $9.40, while AVR trades at $3.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas AVR's P/E ratio is -1.10. In terms of profitability, HSDT's ROE is -4.19%, compared to AVR's ROE of -2.92%. Regarding short-term risk, HSDT is more volatile compared to AVR. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs OWLT Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, OWLT has a market cap of 141M. Regarding current trading prices, HSDT is priced at $9.40, while OWLT trades at $8.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas OWLT's P/E ratio is -5.30. In terms of profitability, HSDT's ROE is -4.19%, compared to OWLT's ROE of +1.25%. Regarding short-term risk, HSDT is more volatile compared to OWLT. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs BDMD Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, BDMD has a market cap of 139.7M. Regarding current trading prices, HSDT is priced at $9.40, while BDMD trades at $3.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas BDMD's P/E ratio is 7.98. In terms of profitability, HSDT's ROE is -4.19%, compared to BDMD's ROE of +0.12%. Regarding short-term risk, HSDT is more volatile compared to BDMD. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs LUNG Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, LUNG has a market cap of 111.9M. Regarding current trading prices, HSDT is priced at $9.40, while LUNG trades at $2.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas LUNG's P/E ratio is -1.93. In terms of profitability, HSDT's ROE is -4.19%, compared to LUNG's ROE of -0.64%. Regarding short-term risk, HSDT is more volatile compared to LUNG. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs LUCD Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, LUCD has a market cap of 111.4M. Regarding current trading prices, HSDT is priced at $9.40, while LUCD trades at $1.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas LUCD's P/E ratio is -0.88. In terms of profitability, HSDT's ROE is -4.19%, compared to LUCD's ROE of +26.96%. Regarding short-term risk, HSDT is more volatile compared to LUCD. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs MGRM Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, MGRM has a market cap of 103.5M. Regarding current trading prices, HSDT is priced at $9.40, while MGRM trades at $2.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas MGRM's P/E ratio is -5.80. In terms of profitability, HSDT's ROE is -4.19%, compared to MGRM's ROE of -1.26%. Regarding short-term risk, HSDT is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.
HSDT vs ICAD Comparison
HSDT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HSDT stands at 71M. In comparison, ICAD has a market cap of 103.3M. Regarding current trading prices, HSDT is priced at $9.40, while ICAD trades at $3.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HSDT currently has a P/E ratio of -0.36, whereas ICAD's P/E ratio is -19.79. In terms of profitability, HSDT's ROE is -4.19%, compared to ICAD's ROE of -0.17%. Regarding short-term risk, HSDT is more volatile compared to ICAD. This indicates potentially higher risk in terms of short-term price fluctuations for HSDT.